New Delhi, 3 May (IANS). CRISPR/CAS 9 Jean Editing Technology named CRISPR/CAS 9 has given good results in fighting colon and intestinal advance cancer. This information has been revealed by the report of the first human test (Clinical Trial) published in an international medical journal The Lancet Oncology.
In this research, scientists replaced a particular type of pathological cell (called tumor-inflammatory lymphocytes or TILS) through gene editing. He closed a gene named CISH. As a result, these changed cells began to identify and destroy cancer cells better than before.
Doctor Emil Lou, University of Minnesota, said, “Despite a lot of research on cancer, Stage 4 Colorectal Cancer is still incurable in most cases.” His colleague Professor Brandon Moriyriti reported that this gene named CISH prevents cancer -fighting cells from functioning properly. CRISPR technology was used to prevent this, so CRISPR technology was used.
This treatment was tried on 12 patients whose cancer had spread too much. No one suffered any serious side effects due to treatment. In many patients, cancer stopped growing and in a patient, the cancer was completely over. Cancer in that person did not return again for two years.
Unlike other cancer drugs, this gene editing is done once and then this change remains permanently in body cells.
Dr. Lou said, “Research in our laboratory is now reaching patients, and this treatment can give new hope for advance cancer patients.”
Scientists reported that they gave more than 10 billion changed TIL cells in the body without any loss, which had never been possible before.
Although this treatment looks effective, it is still very expensive and technically complex. Scientists say that it is important to understand what reasons this treatment could do so well in some patients.
-IANS
AS/
